

Mark Scheme (Results)

October 2020

Pearson Edexcel International Advanced Level In Biology (WBI11) Paper 01 Molecules, Diet, Transport and Health

| Question number | Answer | Additional guidance | Mark |
|-----------------|--|--|------|
| 1(a) | | | |
| i(u) | peptide (1) | DO NOT ACCEPT dipeptide / polypeptide / amide | |
| | amino / NH_2 / NH_3^+ / amine (1) | les 21 character at 1 | |
| | carboxyl / COOH / CO₂H / COO⁻ / carboxylic (acid)(1) | ACCEPT second and third point either way round | |
| | condensation (1) | ACCEPT polymerisation / addition elimination | |
| | translation (1) | | (5) |

| Question number | Answ | Answer | | | | | Mark | |
|--------------------|------|-----------------------------|---------------------|------------------|-------------------------------|-----------------------|------|-----|
| 1(b) | | Structure | Hydrogen bonds only | lonic bonds only | Both hydrogen and ionic bonds | Neither of these bond | | |
| | | secondary structure | X | X | X | X | | |
| | | three-dimensional structure | $oxed{x}$ | $oxed{x}$ | X | oxdeta | | (2) |

| Question | Answer | Additional guidance | Mark |
|----------|------------------------------|-------------------------------------|------|
| number | | | |
| 2(a) | | IGNORE VI VI VI | |
| | and in this of all along (4) | IGNORE genetic composition / | |
| | combination of alleles (1) | combination of information carried | |
| | | in the genes / all genetic | |
| | | {information / make up} | |
| | | DO NOT ACCEPT genes | |
| | | | (1) |

| Question number | Answer | Additional guidance | Mark |
|-----------------|----------------------------------|----------------------------------|------|
| 2(b) | • 1 in 2 / 50:50 / 50% / 0.5 / ½ | ACCEPT 2 in 4 / 1:1 / 2:2 | (1) |

| Question number | Answer | Additional guidance | Mark |
|-----------------|---|---|------|
| 2(c) | An answer that makes reference to the following points: | CEs throughout | |
| | • parents shown as heterozygotes (1) | ACCEPT any pair of letters chosen to represent alleles from Punnet square | |
| | genotypes of offspring shown (1) | | |
| | • 3 (orange): 1 (white) (1) | ACCEPT 1 white : 3 orange | (3) |

| Question | Answer | Additional guidance | Mark |
|----------|--|------------------------------|------|
| number | | | |
| 2(d) | 1:- 20 / 0 02 / 2 20/ / 1/- | ACCEPT 0.03 recurring / 3.3% | |
| | • 1 in 30 / 0.03 / 3.3% / ¹ / ₃₀ | recurring | (1) |

| Question number | Answer | | | | Mark |
|-----------------|-------------------------------|---|--------------------|--|------|
| 3(a)(i) | The only correct answer is B | | | | |
| | | contracted | relaxed | | |
| | A is incorrect because | e the ventricles are relaxed | | | |
| | C is incorrect because | e the atria are contracted and the vent | ricles are relaxed | | |
| | D is incorrect because | se the atria are contracted | | | (1) |

| Question | Answer | Additional guidance | Mark |
|----------|--|---|------|
| number | | | |
| 3(a)(ii) | An explanation that includes the following points: | | |
| | because the atrioventricular valves have to close (before the ventricles contract) (1) | ACCEPT {bicuspid / mitral} valve and tricuspid valve DO NOT ACCEPT valves close during ventricular systole | |
| | to prevent backflow of blood into the atria (1) | | |
| | | | (2) |

| Question number | Answer | Additional guidance | Mark |
|-----------------|---|---|------|
| 3(a)(iii) | cardiac cycle time multiplied by proportion of cycle spent in | Example of calculation: 0.86 × 3/8 / 0.3225 / 0.32 / 0.323 | |
| | ventricular systole (1) • $3.2 \times 10^2 / 3.23 \times 10^2$ (1) | Correct answer with no working gains 2 marks | (2) |

| Question number | Answer | Additional guidance | Mark |
|-----------------|--------------------|--|------|
| 3(a)(iv) | • 63% / 5/8 / 0.63 | ACCEPT 0.625 / 62.5% / 5 out of 8 | |
| | | | (1) |

| Question | Answer | Additional guidance | Mark |
|----------------|---|---|------|
| number 3(b) | | Example of calculation: | |
| 3(5) | | Example of calculation. | |
| | heart rate if cardiac cycle lasts 0.86 seconds (1) | 60 ÷ 0.86 = 69.76744186046512 | |
| | heart rate if cardiac cycle last 0.46 seconds (1) | 60 ÷ 0.46 = 130.4347826 | |
| | | Answer in range of 60.2 to 60.7 gains 2 marks | |
| | • increase in heart rate = 60 / 61 beats per minute (1) | CE from calculations of heart rate | |
| | | Correct answer alone gains 3 marks | (3) |

| Question | Answer | Additional guidance | Mark |
|----------|---|-------------------------------|------|
| number | | | |
| 4(a)(i) | | | |
| | circle drawn around R, the attached sugar and a phosphate group | | |
| | | | |
| | | Y-0::0-Q | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | % | |
| | | 7 | |
| | | | |
| | | ACCEPT the phosphate group on | |
| | | either C3 or C5 | |
| | | | (1) |

| Question number | Answer | | | | Mark |
|-----------------|------------------------------------|----------------------------------|----------------------------|-------------|------|
| 4(a)(ii) | The only correct answer is D | | | | |
| | | phosphodiester | covalent | hydrogen | |
| | A is incorrect because S is | a phosphodiester bond, T is a co | ovalent bond and U is a hy | drogen bond | |
| | B is incorrect because S is | a phosphodiester bond and U is | a hydrogen bond | | |
| | C is incorrect because T is | a covalent bond and U is a hydr | ogen bond | | (1) |

| Question | Answer | Mark |
|-----------|---|------|
| number | | |
| 4(a)(iii) | The only correct answer is C Thymine | |
| | | |
| | A is incorrect because adenine is complementary to thymine | |
| | | |
| | B is incorrect because adenine is complementary to thymine | |
| | | |
| | D is incorrect because adenine is complementary to thymine | (1) |

| Question number | Answer | Additional guidance | Mark |
|-----------------|---|-------------------------|------|
| 4(b)(i) | A diagram that shows the following points: • a band the same width as stage 1 in the middle of the tube (1) | DNA taken after stage 2 | |
| | bands drawn at the top and middle of tube (1) both bands narrower than stage 1 (1) | DNA taken after stage 3 | |
| | bands drawn at the top and middle of tube (1) top band drawn narrower than stage 1 but wider than stage 3 and lower band drawn narrower than stage 3 (1) | DNA taken after stage 4 | (5) |

| Question | Answer | Mark |
|----------|---|------|
| number | | |
| 4(b)(ii) | | |
| | The only correct answer is B | |
| | | |
| | | |
| | A is incorrect because neither DNA molecule is made of all heavy nitrogen or light nitrogen | |
| | | |
| | C is incorrect because neither DNA molecule is made of all heavy nitrogen or light nitrogen + bands are too wide | |
| | | (4) |
| | D is incorrect because it has only one band | (1) |

| Question number | Answer | Additional guidance | Mark |
|-----------------|---|--|------|
| 5(a) | ACCEPT any two from : | IGNORE risk factors | |
| | BMI / body mass index | ACCEPT mass ÷ height² / weight ÷ height² | |
| | waist to hip ratio / hip to waist ratio | | |
| | waist to height ratio / height to waist ratio | | |
| | waist circumference | | |
| | skin fold (thickness) | | (1) |
| | | | (1) |

| Question number | Answer | Mark |
|-----------------|---|------|
| 5(b)(i) | The only correct answer is B | |
| | B 1-6 only | |
| | A is incorrect because 1-4 bonds are present in straight chains only | |
| | C is incorrect because 1-4 bonds are present in straight chains only | |
| | D is incorrect because 1-6 bonds form the branches | (1) |

| Question | Answer | Additional guidance | Mark |
|----------|---|--|------|
| number | | | |
| 5(b)(ii) | makes the person feel full / prevents so much food from being in the stomach / fills up the stomach so less food needed to satisfy hunger / glucomannan takes the space of the food (1) | IGNORE: reduces food intake decreases volume of stomach | |
| | | | (1) |

| Question | Answer | Additional guidance | Mark |
|-----------|--|--|------|
| number | | | |
| 5(b)(iii) | An explanation that includes the following points: | | |
| | because it contains lots of {monosaccharides / glucose / energy} (1) | ACCEPT sugar for glucose polymer of glucose lots of mannose broken down into lots of {glucose / monosaccharides / | |
| | therefore {energy input could be greater than energy output / (excess) glucose converted to fat} (1) | mannose} ACCEPT excess energy stored as fat | |
| | glucomannan would no longer be filling up the stomach so more food could be eaten (1) | | (2) |

| Question number | Answer | Additional guidance | Mark |
|-----------------|--|---|------|
| 5(c)(i) | An answer that includes the following points: | | |
| | group on low fat diet lost 4.3 (kg) and group on very low- carbohydrate diet lost 8.1 (kg) (1) | ACCEPT group on low fat diet lost 3.8 (kg) more | |
| | • (overall) loss of 8.1 (kg) is {1.88 / 1.9} times more weight (1) | ACCEPT about twice as much / for low-fat diet this is 4.6% of starting weight and for very low-carbohydrate 8.9% starting weight | |
| | which is slightly lower than the other studies are claiming (1) | | |
| | | ACCEPT results are at the lower end of | |
| | claims are referring to low-carbohydrate diet but this one is a | the claim | |
| | very low-carbohydrate diet (1) | | (3) |

| Question number | Answer | Additional guidance | Mark |
|-----------------|--|---------------------------------|------|
| 5(c)(ii) | An answer that includes two of the following points: | IGNORE other named risk factors | |
| | (blood) {cholesterol / LDL} levels (1) | ACCEPT LDL : HDL | |
| | blood pressure (1) | | |
| | • heart rate (1) | | (2) |
| | | | (2) |

| Question | Answer | Additional guidance | Mark |
|----------|--|--|------|
| number | In directive an extension | | |
| *6(a) | Indicative content: triplet codon system (D) because (at least) 20 codes needed for the amino acids (E) e.g. AAC is code for asparagine (x) | ACCEPT three bases code for one amino acid ACCEPT each amino acid has its own code | |
| | degenerate code (D) | | |
| | therefore some amino acids have more than one code (E) | ACCEPT there are more codes than necessary | |
| | e.g. threonine can be coded for by ACA, ACC, ACG or ACT (x) | | |
| | non-overlapping code (D) | | |
| | so each base on DNA is used in only one triplet codon (E) | ACCEPT discrete | (5) |
| | e.g. AAC AGA codes for two amino acids (x) | | (6) |

Level 1: refers to triplet codon system, degenerative code **or** non-overlapping code but no examples or explanation given 1 mark = 1 out of 3

2 marks = 2 out of 3 or 1 out of 3 + a linked example or explanation

 $\textbf{Level 2:} \ \text{refers to triplet codon system, degenerative code} \ \textbf{or} \ \text{non-overlapping code with either examples or explanation given}$

3 marks = at least 2 examples or 2 explanations or 1 of each

4 marks = at least 3 examples or 3 explanations or any combination of each

Level 3: refers to triplet codon system, degenerative code **and** non-overlapping code with examples and explanation given

5 marks = at least 4 examples or explanations or any combination of each

6 marks = at least 5 examples or explanations or any combination of each

| Question number | Answer | Additional guidance | Mark |
|-----------------|--|---|------|
| 6(b)(i) | methionine alanine cysteine proline isoleucine leucine | ACCEPT phonetic spelling / reasonable abbreviations / M A C P I L | (1) |

| Question number | Answer | Additional guidance | Mark |
|-----------------|--|---|------|
| 6(b)(ii) | An explanation that includes the following points: it will have no effect (on the polypeptide) if the ninth base becomes a T as this still codes for {cysteine / same amino acid} (1) | | |
| | will code for a stop codon if the ninth base becomes an A (1) therefore the {protein / polypeptide} will be {shorter / not formed} (1) | ACCEPT only two amino acids will join together | |
| | will code for tryptophan if the ninth base becomes G (1) | | |
| | this could change the bonding in the protein (1) shanging the (structure / activity) of the protein (1) | ACCEPT even if tryptophan not given / given wrongly ACCEPT even if tryptophan not given / given wrongly | |
| | changing the {structure / activity} of the protein (1) | given wrongly | (5) |

| Question | Answer | Additional guidance | Mark |
|----------|--|--|------|
| number | | | |
| 7(a) | A description that includes the following point: | | |
| | to be present in the blood (all the time) (1) | ACCEPT precursor of clotting process / inactive form of thrombin / inactive enzyme / inactive plasma protein | |
| | and any TWO of the following: | | |
| | needed to make thrombin (when blood needs to clot) (1) | | |
| | • which is an {enzyme / catalyst} (1) | | |
| | so that fibrinogen can be converted into fibrin (1) | | |
| | | NB thrombin catalyses fibrinogen into | |
| | | fibrin = 2 marks | (3) |

| Question | Answer | Mark |
|----------|--|------|
| number | | |
| 7(b) | The only correct answer is A | |
| | A anticoagulant | |
| | B is incorrect because antihypertensives treat high blood pressure | |
| | C is incorrect because platelet inhibitors inhibit platelets, which are involved in the cascade before prothrombin and prothrombin is made by the liver | |
| | D is incorrect because statins treat high blood cholesterol levels | (1) |

| Question number | Answer | Additional guidance | Mark |
|-----------------|--|---|------|
| 7(c)(i) | An answer that includes the following points: | | |
| | warfarin and vitamin K have a similar structure (1) | ACCEPT both have rings / double bond oxygen | |
| | therefore warfarin {binds / blocks} to the {vitamin K epoxide reductase / VKOR} (1) | ACCEPT warfarin is a {competitive / active-site directed } inhibitor / description DO NOT ACCEPT non-competitive inhibitor / description of one binds to vitamin K | |
| | (as a result of warfarin binding to enzyme) {less / no} vitamin K reduced (1) | | (2) |

| Question | Answer | Additional guidance | Mark |
|----------|---|--|------|
| number | | | |
| 7(c)(ii) | An answer that includes the following points: | | |
| | • increase in vitamin K would compete with warfarin for the active site (of vitamin K epoxide reductase / VKOR) (1) | ACCEPT a description e.g. more enzyme substrate complexes | |
| | therefore {some / more} vitamin K will be reduced (if vitamin K binds to enzyme) (1) | | |
| | | | (2) |

| Question number | Answer | Additional guidance | Mark |
|-----------------|---|--|------|
| 7(d) | An explanation that includes the following points: | | |
| | large groups of people (1) | ACCEPT 20 + IGNORE reference to control groups | |
| | (sample size is large) for reproducibility (1) | ACCEPT repeatable / reliable IGNORE accurate / precise / valid | |
| | people in both groups consume the same {mass / volume / concentration} of vitamin K (1) | IGNORE amount | |
| | people in both groups consume the same concentration of drugs (1) | ACCEPT other appropriate named control variable e.g. sex, age, diet, level of activity, alcohol intake IGNORE same number of people in each group / amount | |
| | • (variables controlled) for validity (1) | IGNORE accurate / precise /reproducible / repeatable / reliable | (4) |

| Question number | Answer | Additional guidance | Mark |
|-----------------|---|--|------|
| 8(a) | An answer that includes three of the following points: | | |
| | Similarities | NB Do not piece together from two descriptions in separate sentences IGNORE diagrams | |
| | Any two from: | , and the second | |
| | both contain a glycerol (1) | | |
| | both contain fatty acids (1) | | |
| | both contain ester bonds (1) | | |
| | Differences | | |
| | triglycerides have three fatty acids and phospholipids have two fatty acids (1) | | |
| | triglycerides do not contain a phosphate group but phospholipids do contain a phosphate group (1) | | (3) |

| Question number | Answer | Additional guidance | Mark |
|-----------------|--|---------------------|------|
| 8(b) | An explanation that includes the following points: {protein / phosphate heads / phospholipid heads} are {soluble / hydrophilic / polar} and interact with {blood / plasma} (1) {fatty acids / triglycerides /cholesterol} is {insoluble / non-polar / hydrophobic} (1) | | |
| | therefore cholesterol is surrounded by {fatty acid tails / triglycerides} (1) | | (3) |

| Question number | Answer | Additional guidance | Mark |
|-----------------|---|---|------|
| 8(c)(i) | volume of sphere calculated / values substituted into the equation (1) | Example of calculation = 6912 if using $\pi = 3$ = 7142.4 if using $\pi = 3.1$ = 7234.56 if using $\pi = 3.14$ = 7239.168 if using $\pi = 3.142$ = 7241.472 if using $\pi = 3.143$ = 7238.22947387 if pressing π on calculator | |
| | volume of sphere rounded up to nearest whole number (1) = 6912 / 7142 / 7235 / 7239 / 7238 / 7241 ACCEPT 6910 / 7140 / 7240 NB Just these values given = 2 marks | | |
| | • ratio calculated (1) | 14:1 13:1 if 6910 / 6912 CE apply throughout NB mark answer in table if different from in the working e.g. | |
| | | | |
| | | Diameter Volume of Cholesterol volume to cholesterol volume | |
| | | 7235 14:1 | |
| | | | (3) |

| Question number | Answer | Additional guidance | Mark |
|-----------------|---|---------------------|------|
| *8(c)(ii) | Indicative content: | | |
| | as LDL increases, risk increases (K / G) | | |
| | several factors beside LDLs can increase the risk of CVD (K) | | |
| | example of a factor given e.g. high blood pressure (K) | | |
| | LDLs can be different sizes (Q) | | |
| | and therefore be absorbed by endothelial cells differently (Q) | | |
| | and therefore get broken down at different rates (K / Q) | | |
| | and therefore carry different volumes of cholesterol (Q) | | |
| | level of HDL (in blood) affects risk (of CVD) (K / G) | | |
| | example given from graph e.g. 0.65 a.u. has greater risk than 2.20 a.u. (G) | | |
| | • ratio of LDL : HDL affects risk (of developing CVD) (K / G) | | |
| | • the lower LDL : HDL the ratio the lower risk of CVD (K / G) | | (6) |

Own knowledge (K), information given in the graph (G), information in the question (Q)

Level 1: uses either (K), (G) or (Q) 1 mark = 1 comment, 2 marks = 2 comments

Level 2: uses two from (K), (G) or (Q) 3 marks = 3 comments, 4 marks = 4 comments

Level 3: uses (K), (G) and (Q) 5 marks = 5 comments, 6 marks = 6 comments